NCT02519452 2025-05-23A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple MyelomaJanssen Research & Development, LLCPhase 1 Completed120 enrolled